Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2013 1
2014 3
2015 5
2016 3
2017 4
2018 3
2019 2
2020 2
2021 2
2022 1
2023 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study.
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N; iFACT3 study team. Hiransuthikul A, et al. Among authors: thammajaruk n. J Int AIDS Soc. 2025 May;28(5):e26502. doi: 10.1002/jia2.26502. J Int AIDS Soc. 2025. PMID: 40390323 Free PMC article. Clinical Trial.
Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.
Punyawudho B, Singkham N, Thammajaruk N, Dalodom T, Kerr SJ, Burger DM, Ruxrungtham K. Punyawudho B, et al. Among authors: thammajaruk n. Expert Rev Clin Pharmacol. 2016 Dec;9(12):1583-1595. doi: 10.1080/17512433.2016.1235972. Epub 2016 Sep 23. Expert Rev Clin Pharmacol. 2016. PMID: 27626677 Review.
Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand.
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N; iMACT study team. Hiransuthikul A, et al. Among authors: thammajaruk n. J Int AIDS Soc. 2025 Apr;28(4):e26445. doi: 10.1002/jia2.26445. J Int AIDS Soc. 2025. PMID: 40195242 Free PMC article. Clinical Trial.
Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
Punyawudho B, Thammajaruk N, Thongpeang P, Matthews G, Lewin SR, Burger D, Ruxrungtham K, Avihingsanon A. Punyawudho B, et al. Among authors: thammajaruk n. Int J Clin Pharmacol Ther. 2015 Nov;53(11):947-54. doi: 10.5414/CP202386. Int J Clin Pharmacol Ther. 2015. PMID: 26308175
Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women.
Landolt NK, Phanuphak N, Ubolyam S, Pinyakorn S, Kerr S, Ahluwalia J, Thongpaeng P, Thammajaruk N, Cremers S, Thomas T, Chaithongwongwatthana S, Lange JM, Ananworanich J. Landolt NK, et al. Among authors: thammajaruk n. J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):e50-2. doi: 10.1097/QAI.0000000000000134. J Acquir Immune Defic Syndr. 2014. PMID: 24608892 No abstract available.
Pharmacokinetics of rilpivirine and 24-week outcomes after switching from efavirenz in virologically suppressed HIV-1-infected adolescents.
Jantarabenjakul W, Anugulruengkitt S, Kasipong N, Thammajaruk N, Sophonphan J, Bunupuradah T, Cressey TR, Colbers A, Burger DM, Phongsamart W, Puthanakit T, Pancharoen C; HIVNAT 220 study. Jantarabenjakul W, et al. Among authors: thammajaruk n. Antivir Ther. 2018;23(3):259-265. doi: 10.3851/IMP3198. Antivir Ther. 2018. PMID: 28994660
28 results